Harmony Biosciences Holdings, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) resulting from allegations that Harmony Biosciences may have issued materially misleading business information to the investing public.

If you purchased Harmony Biosciences securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Harmony Biosciences securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On March 28, 2023, before the market opened, market analyst Scorpion Capital published a report on Harmony Biosciences. The report alleged, among other things, that Harmony’s drug, Wakix (pitolisant), is unsafe and causes heart-related issues (including sudden cardiac death) to occur in patients who are otherwise healthy. The report further alleged that, to obtain approval for Wakix from the United States Food & Drug Administration (“FDA”), Harmony Biosciences obtained approval in foreign nations with allegedly lax drug safety controls, such as Russia, before tricking the FDA into approving the drug based on the prior approvals. The report also alleged that the company engaged in kickback schemes to pay physicians to use its drugs, has a sham patent portfolio, and engages in false advertising.

On this news, Harmony Bioscience’s stock price fell as much as $11.34 per share, or 27.33%, in intraday trading.

公司名称: Harmony Biosciences Holdings, Inc.
股票代号: HRMY
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。